[go: up one dir, main page]

BR112017006272A2 - composição farmacêutica para tratar colite ulcerativa. - Google Patents

composição farmacêutica para tratar colite ulcerativa.

Info

Publication number
BR112017006272A2
BR112017006272A2 BR112017006272-0A BR112017006272A BR112017006272A2 BR 112017006272 A2 BR112017006272 A2 BR 112017006272A2 BR 112017006272 A BR112017006272 A BR 112017006272A BR 112017006272 A2 BR112017006272 A2 BR 112017006272A2
Authority
BR
Brazil
Prior art keywords
ulcerative colitis
medical treatment
chronic ulcerative
medicine constituent
constituent
Prior art date
Application number
BR112017006272-0A
Other languages
English (en)
Japanese (ja)
Inventor
Kageyama Shunsuke
Goda Yoshiki
Sugiura Toshihiko
Original Assignee
Ea Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ea Pharma Co., Ltd. filed Critical Ea Pharma Co., Ltd.
Publication of BR112017006272A2 publication Critical patent/BR112017006272A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

é provida uma composição farmacêutica que é para tratar colite ulcerativa e inclui um composto representado pela fórmula (1) ou um sal farmaceuticamente aceitável do mesmo, em que o dito composto ou sal farmaceuticamente aceitável do mesmo é administrado a um paciente tendo colite ulcerativa em uma dose de pelo menos 600 mg por dia.
BR112017006272-0A 2014-09-29 2015-03-27 composição farmacêutica para tratar colite ulcerativa. BR112017006272A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014198681 2014-09-29
JP2014-198681 2014-09-29
PCT/JP2015/059717 WO2016051828A1 (ja) 2014-09-29 2015-03-27 潰瘍性大腸炎の治療用医薬組成物

Publications (1)

Publication Number Publication Date
BR112017006272A2 true BR112017006272A2 (pt) 2018-03-13

Family

ID=55629887

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006272-0A BR112017006272A2 (pt) 2014-09-29 2015-03-27 composição farmacêutica para tratar colite ulcerativa.

Country Status (9)

Country Link
US (1) US10183022B2 (pt)
JP (1) JP6580053B2 (pt)
KR (1) KR102319078B1 (pt)
AU (1) AU2015326196B2 (pt)
BR (1) BR112017006272A2 (pt)
CA (1) CA2961311C (pt)
EA (1) EA034956B1 (pt)
MX (1) MX381440B (pt)
WO (1) WO2016051828A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3514235T (pt) * 2018-01-18 2024-02-12 Sterna Biologicals Gmbh Composição para o tratamento de um doente que sofre de colite ulcerosa, assim como utilização da composição como medicamento
EP3873884B1 (en) 2018-10-30 2024-12-04 Gilead Sciences, Inc. 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dione derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
CN112969504B (zh) 2018-10-30 2024-04-09 吉利德科学公司 用于抑制α4β7整合素的化合物
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof
KR102758046B1 (ko) 2021-11-05 2025-01-23 (주) 넥셀 궤양성 대장염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 궤양성 대장염 예방 또는 치료용 조성물
CN114668775B (zh) * 2022-02-28 2023-12-19 中国药科大学 纤维素衍生物在制备治疗溃疡性结肠炎药物中的应用
CN118871130A (zh) 2022-03-11 2024-10-29 国立大学法人大阪大学 包含vla-4阻断物质的用于预防或治疗心肌炎的组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228914B1 (hu) 2000-08-18 2013-06-28 Ajinomoto Kk Fenilalanin-származékok
CN101386600B (zh) 2003-02-20 2011-07-06 味之素株式会社 具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体
EP3216449A1 (en) 2003-11-14 2017-09-13 EA Pharma Co., Ltd. Oral administration preparation of phenylalanine derivatives
DK1683524T3 (da) 2003-11-14 2011-03-14 Ajinomoto Kk Dispergering på fast form eller medicinsk præparat på fast form af phenyalaninderivat
WO2005051525A1 (en) 2003-11-25 2005-06-09 Polyvalor, Limited Partnership Permeation barrier coating or layer with modulated properties and methods of making the same
EP1688410B1 (en) 2003-11-27 2014-03-05 Ajinomoto Co., Inc. Crystal of phenylalanine derivative and process for producing the same
WO2006137450A1 (ja) 2005-06-21 2006-12-28 Ajinomoto Co., Inc. フェニルアラニン誘導体の結晶、その製造方法及びその使用
WO2008062859A1 (fr) 2006-11-22 2008-05-29 Ajinomoto Co., Inc. Procédé de fabrication de dérivés de phénylalanine ayant des squelettes de quinazolinedione et intermédiaires pour la fabrication
US7987289B2 (en) 2008-06-24 2011-07-26 Microsoft Corporation Participating in cloud as totally stubby edge
EP2853529A1 (en) * 2010-03-29 2015-04-01 Ajinomoto Co., Inc. Crystals of salts of phenylalanine derivatives
CN102905707A (zh) 2010-03-29 2013-01-30 味之素株式会社 含有苯基丙氨酸衍生物的医药制剂

Also Published As

Publication number Publication date
AU2015326196A1 (en) 2017-03-23
JPWO2016051828A1 (ja) 2017-07-27
EA201790726A1 (ru) 2017-11-30
MX2017003780A (es) 2017-06-30
CA2961311C (en) 2022-12-06
JP6580053B2 (ja) 2019-09-25
AU2015326196B2 (en) 2020-05-14
US10183022B2 (en) 2019-01-22
EA034956B1 (ru) 2020-04-10
CA2961311A1 (en) 2016-04-07
WO2016051828A1 (ja) 2016-04-07
MX381440B (es) 2025-03-12
US20170196870A1 (en) 2017-07-13
KR102319078B1 (ko) 2021-10-29
KR20170057435A (ko) 2017-05-24

Similar Documents

Publication Publication Date Title
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
PH12016502352A1 (en) Pharmaceutical composition
CO2016003340A2 (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
TW201613578A (en) Pharmaceutical combinations
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
BR112018068784A2 (pt) método para o tratamento de leucemia
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
BR112016027435A2 (pt) formulação inovadora de meloxicam
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
MX2017015664A (es) Administracion intravenosa de citrulina durante cirugia.
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
AR102308A1 (es) Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX387263B (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma.
BR112018068910A2 (pt) sultiame para o tratamento de apneia do sono
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]